Abstract：
Carpal Tunnel Syndrome (CTS) is provoked by the compression of the median nerve, leading to nerve ischemia, endoneural edema, venous congestion, and subsequent metabolic alterations. Conservative treatments could be considered. The present study investigates the efficacy of a specific blend of a 600 mg dietary integrator composed of acetyl-L-carnitine, α-lipoic acid, phosphatidylserine, Curcumin, C, E and B1, B2, B6 and B12 vitamins in patients with mild to moderate CTS.
The present investigation involved the outpatients who were planned to undergo open surgical decompression of the median nerve awaiting surgery from June 2020 and February 2021. CTS surgery has been significantly reduced in our institutions during the COVID-19 pandemic. Patients were randomized into Group A (dietary integration 600 mg twice day for 60 days) and Group B (control group, no drug administration). Clinical and functional improvement was prospectively measured after 60 days Results: One-hundred forty-seven patients completed the study, 69 from group A and 78 from group B. BCTQ was significantly improved with the drug administration, as well as BCTQ symptoms subscale, and the pain. BCTQ function subscale and Michigan Hand Questionnaire was not significantly improved. Ten patients in group A (14.5%) declared that they didn\'t need further treatment. No major side effects were noticed.
Dietary integration could be considered as an option in patients who could not undergo surgery. Symptoms and pain could improve, but surgery remains the gold standard for recovery of function in mild to moderate CTS.
The present investigation involved the outpatients who were planned to undergo open surgical decompression of the median nerve awaiting surgery from June 2020 and February 2021. CTS surgery has been significantly reduced in our institutions during the COVID-19 pandemic. Patients were randomized into Group A (dietary integration 600 mg twice day for 60 days) and Group B (control group, no drug administration). Clinical and functional improvement was prospectively measured after 60 days Results: One-hundred forty-seven patients completed the study, 69 from group A and 78 from group B. BCTQ was significantly improved with the drug administration, as well as BCTQ symptoms subscale, and the pain. BCTQ function subscale and Michigan Hand Questionnaire was not significantly improved. Ten patients in group A (14.5%) declared that they didn\'t need further treatment. No major side effects were noticed.
Dietary integration could be considered as an option in patients who could not undergo surgery. Symptoms and pain could improve, but surgery remains the gold standard for recovery of function in mild to moderate CTS.
摘要：
目的：腕管综合征（CTS）是由正中神经压迫引起的，导致神经缺血，神经内膜水肿,静脉充血,以及随后的代谢改变。可以考虑保守治疗。本研究调查了由乙酰-L-肉碱，α-硫辛酸,磷脂酰丝氨酸,姜黄素,C,E和B1，B2，B6和B12维生素在轻度至中度CTS患者中。
方法：本调查涉及计划于2020年6月至2021年2月进行正中神经开放手术减压的门诊患者。在COVID-19大流行期间，我们机构的CTS手术已大大减少。患者随机分为A组（饮食整合600mg，每天两次，共60天）和B组（对照组，无药物管理)。60天后前瞻性地测量临床和功能改善结果：一百四十七名患者完成了研究，A组69例，B组78例。BCTQ随着给药而显著提高，以及BCTQ症状分量表，还有疼痛.BCTQ功能分量表和密歇根手问卷没有明显改善。A组10例(14.5%)患者表示不需要进一步治疗。没有发现重大副作用。
结论：饮食整合可作为不能接受手术的患者的一种选择。症状和疼痛可以改善，但手术仍是轻中度CTS功能恢复的金标准.
方法：本调查涉及计划于2020年6月至2021年2月进行正中神经开放手术减压的门诊患者。在COVID-19大流行期间，我们机构的CTS手术已大大减少。患者随机分为A组（饮食整合600mg，每天两次，共60天）和B组（对照组，无药物管理)。60天后前瞻性地测量临床和功能改善结果：一百四十七名患者完成了研究，A组69例，B组78例。BCTQ随着给药而显著提高，以及BCTQ症状分量表，还有疼痛.BCTQ功能分量表和密歇根手问卷没有明显改善。A组10例(14.5%)患者表示不需要进一步治疗。没有发现重大副作用。
结论：饮食整合可作为不能接受手术的患者的一种选择。症状和疼痛可以改善，但手术仍是轻中度CTS功能恢复的金标准.
